Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion
β Scribed by Yasuyuki Yamashita; Mutsumasa Takahashi; Yukinori Koga; Ryuiti Saito; Seito Nanakawa; Yoshimi Hatanaka; Nobuyuki Sato; Koki Nakashima; Joji Urata; Kazuhiro Yoshizumi; Koshiro Ito; Seiya Sumi; Masayasu Kan
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 532 KB
- Volume
- 67
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Systemic, highβdose interferonβΞ± treatment given three times per week subcutaneously induces tumor regression in approximately 30% of patients with inoperable hepatocellular carcinoma (HCC). The objective of the current study was to determine the efficacy and safety of tr
## Abstract Transcatheter arterial embolization (TAE) destroys a tumor by the induction of necrosis and/or apoptosis and causes inflammation with cytokine production, which may favor immune activation and presentation of tumorβspecific antigens. In the current study, we attempted to identify the ef
Background. Because transcatheter arterial embolization (TAE) has been shown to be effective in patients with unresectable hepatocellular carcinoma (HCC), the question arises whether TAE has an equivalent or superior effect on resectable HCC compared with surgery. To clarify this point, the authors